The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes

Pharmacogenetics and Genomics

Volumn 23, Issue 4, 2013, Pages 219-227

  Stage, Tore B ^a   Christensen, Mette M H ^a   Feddersen, Søren ^b   Beck Nielsen, Henning ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CYP2C8; LPIN1; pharmacogenetics; PPARGC1A; PPAR ; rosiglitazone; type 2 diabetes

Indexed keywords

CYTOCHROME P450 2C8; HEMOGLOBIN A1C; INSULATARD FLEXPEN; INSULIN ASPART; ISOPHANE INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG BLOOD LEVEL; EDEMA; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; LPIN1 GENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STEADY STATE; WILD TYPE;

EID: 84874945128     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835f91fc     Document Type: Article

References (46)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829-841.
2. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284:751-759.
3. Phan J, Reue K. Lipin, a lipodystrophy and obesity gene. Cell Metab 2005; 1:73-83.
4. Phan J, Peterfy M, Reue K. Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J Biol Chem 2004; 279:29558-29564.
5. Zhang P, Takeuchi K, Csaki LS, Reue K. Lipin-1 phosphatidic phosphatase activity modulates phosphatidate levels to promote peroxisome proliferator-activated receptor gamma (PPARgamma) gene expression during adipogenesis. J Biol Chem 2012; 287:3485-3494.
6. Yao-Borengasser A, Rasouli N, Varma V, Miles LM, Phanavanh B, Starks TN, et al. Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation. Diabetes 2006; 55:2811-2818.
7. Wiedmann S, Fischer M, Koehler M, Neureuther K, Riegger G, Doering A, et al. Genetic variants within the LPIN1 gene, encoding lipin, are influencing phenotypes of the metabolic syndrome in humans. Diabetes 2008; 57: 209-217.
8. Peterfy M, Phan J, Xu P, Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 2001; 27:121-124.
9. Suviolahti E, Reue K, Cantor RM, Phan J, Gentile M, Naukkarinen J, et al. Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet 2006; 15:377-386.
10. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28:772-780.
11. Yu J, Ma K, Qi J, Jin G, Wang Y, Fang S, et al. Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: a single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers. Clin Ther 2008; 30:2272-2279.
12. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48:424-432.
13. Pedersen RS, Damkier P, Brosen K. The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2006; 62:682-689.
14. Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol 2005; 59:70-79.
15. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004; 76:239-249.
16. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46:1319-1323.
17. Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75:157-162.
18. European Medicines Agency. EMA recommends suspension of Avandia, Avandamet and Avaglim. Anti-diabetes medication to be taken off the market; 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2010/09/WC500096996.pdf [Accessed 9 January 2012].
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
20. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170:1191-1201.
21. Mannucci E, Monami M, Di Bari M, Lamanna C, Gori F, Gensini GF, et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010; 143:135-140.
22. Friedrich JO, Beyene J, Adhikari NK. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. BMC Res Notes 2009; 2:5.
23. Dahabreh IJ, Economopoulos K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5:116-120.
24. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama 2007; 298:1189-1195.
25. Hurren KM, Taylor TN, Jaber LA. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes Res Clin Pract 2011; 93:49-55.
26. Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24:626-634.
27. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
28. Louisa M, Takeuchi M, Nafrialdi, Setiabudy R. A meta-analysis on treatment effects of thiazolidinediones for type 2 diabetes mellitus in Asian populations. Acta Med Indones 2011; 43:39-52.
29. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26:825-831.
30. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27:1365-1368.
31. Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78:202-208.
32. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, et al. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001; 44: 1170-1176.
33. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91:3446-3450.
34. Yang Y, Mo X, Chen S, Lu X, Gu D. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 2011; 27:177-184.
35. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 2001; 44: 2220-2226.
36. Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes. Diabetologia 2002; 45:740-743.
37. Zhang KH, Huang Q, Dai XP, Yin JY, Zhang W, Zhou G, et al. Effects of the peroxisome proliferator activated receptor-gamma coactivator-1alpha (PGC-1alpha) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50:1022-1030.
38. Kang ES, Park SE, Han SJ, Kim SH, Nam CM, Ahn CW, et al. LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients. Mol Genet Metab 2008; 95 (1-2):96-100.
39. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006; 80:657-667.
40. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics 2008; 3:7-16.
41. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8&z.ast;3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008; 36:73-80.
42. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21:837-850.
43. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597-607.
44. Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 2011; 34:27-33.
45. Pedersen RS, Brosen K, Nielsen F. HPLC method for determination of rosiglitazone in plasma. Chromatographia 2005; 62 (3-4):197-201.
46. Pedersen RS, Christensen MM, Brosen K. Linkage disequilibrium between the CYP2C19&z.ast;17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol 2012; 68:1463-1464.